Related references
Note: Only part of the references are listed.Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus From the Results of NEOCRTEC5010, a Randomized Multicenter Study
Xuefeng Leng et al.
ANNALS OF SURGERY (2021)
PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer
Taisuke Yagi et al.
ANNALS OF SURGERY (2019)
The Prognostic Value of a Pathologic Complete Response After Neoadjuvant Therapy for Digestive Cancer: Systematic Review and Meta-Analysis of 21 Studies
Tao Wan et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
Ken Kato et al.
FUTURE ONCOLOGY (2019)
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-)181 study.
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
Laura M. McLane et al.
Annual Review of Immunology (2019)
Esophageal and Esophagogastric Junction Cancers, Version 2.2019
Jaffer A. Ajani et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
Intratumoral CD8+T cells with stem cell-like properties: Implications for cancer immunotherapy
Werner Held et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Identifying the source of tumour-infiltrating T cells
Suman Kumar Vodnala et al.
NATURE (2019)
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
Caroline S. Jansen et al.
NATURE (2019)
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus The Phase 2 KEYNOTE-180 Study
Manish A. Shah et al.
JAMA ONCOLOGY (2019)
Defining 'T cell exhaustion'
Christian U. Blank et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Epidemiology of Esophageal Squamous Cell Carcinoma
Christian C. Abnet et al.
GASTROENTEROLOGY (2018)
Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma
Toshihiko Doi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial
Hong Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Moshe Sade-Feldman et al.
CELL (2018)
Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer
Thomas W. Rice et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Integrated genomic characterization of oesophageal carcinoma
Jihun Kim et al.
NATURE (2017)
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population
Genta Sawada et al.
GASTROENTEROLOGY (2016)
Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma
Ling Zhang et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2015)
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi et al.
LANCET ONCOLOGY (2015)
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
Joel Shapiro et al.
LANCET ONCOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma
J. A. Elliott et al.
BRITISH JOURNAL OF SURGERY (2014)
Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901
Christophe Mariette et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Identification of genomic alterations in oesophageal squamous cell cancer
Yongmei Song et al.
NATURE (2014)
Genetic landscape of esophageal squamous cell carcinoma
Yi-Bo Gao et al.
NATURE GENETICS (2014)
Genomic and molecular characterization of esophageal squamous cell carcinoma
De-Chen Lin et al.
NATURE GENETICS (2014)
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
P. van Hagen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival
AC Berger et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
Y Ohigashi et al.
CLINICAL CANCER RESEARCH (2005)
Share Paper
